BillionToOne, Inc. (NASDAQ:BLLN)
| Market Cap | $4.30B-18.3% |
| Revenue (ttm) | $436.87M+71.9% |
| Net Income | $49.39M+447.7% |
| EPS | $0.91+455.9% |
| Shares Out | 47.77M |
| PE Ratio | 87.61 |
| Forward PE | 93.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 819,337 |
| Open | $88.80 |
| Previous Close | $90.20 |
| Day's Range | $88.00 - $91.43 |
| 52-Week Range | $61.96 - $150.44 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | $124.00(+37.90%) |
| Earnings Date | Mar 3, 2027 |
About BLLN
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating BLLN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 3, 2027Earnings report
$BLLN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BLLN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BLLN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BLLN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BLLN Revenue by Segment
| Prenatal | $104.29M | 84.80% |
| Oncology | $17.05M | 13.87% |
| Clinical trial support and other services | $1.64M | 1.33% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BLLN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BLLN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BLLN
| VTIVanguard Morningstar Total Stock Market ETF | $67.05M |
| VBVanguard Morningstar Small-Cap ETF | $59.53M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $33.36M |
| VXFVanguard Extended Market ETF | $28.57M |
| SCHASchwab U.S. Small-Cap ETF | $10.40M |
| LFSCF/M Emerald Life Sciences Innovation ETF | $4.84M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BLLN’s recent data — informational, not investment advice
What’s Behind the Score
News check: Short-seller attack and share decline dominate recent coverage, though defensive response and valuation analyses provide some offset.
Recent Insider Activity
Insider Score Trend Over Time
-36.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| LFSC | F/M Emerald Life Sciences Innovation ETF | 4.63% |
| ADDS | Hedgeye Index Adds ETF | 3.87% |
| SPIT | F/m Emerald Special Situations ETF | 2.18% |
| XHS | State Street SPDR S&P Health Care Services ETF | 1.82% |
| GNOM | Global X - Genomics & Biotechnology ETF | 1.68% |
| PCSG | Polen 5Perspectives Small-Mid Growth ETF | 1.48% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 1.05% |
| WSMD | Wasatch Small/Mid Cap ETF | 0.89% |
| IPO | Renaissance IPO ETF | 0.62% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.59% |
| AIMS | Acuitas Small Cap Active ETF | 0.42% |
| TSEE | T. Rowe Price Small Cap ETF | 0.36% |
Weight is the stock’s share of each fund’s holdings.
